Impact of gabapentinoids’ reclassification policy and COVID-19 on gabapentinoids’ utilization pattern and their associated mortality in Scotland and Northern Ireland: a segmental regression analysis
Gabapentinoid utilization does not appear to have been significantly affected by the reclassification or by COVID-19. Cross-national differences underscore the influence of formulary guidance, highlighting the need for harmonized policies/patient-level research to inform safe prescribing.
Authors
- Amanj Baker Kurdi (ORCID: https://orcid.org/0000-0001-5036-1988)
- M. Azeez
- Sonia Baker
- Abdullah Alrahmani
Institutions
- University of Kirkuk (IQ)
- Hawler Medical University (IQ)
- University of Applied Science and Technology (IR)
- University of Strathclyde (GB)
- Sefako Makgatho Health Sciences University (ZA)
Publication Details
- Journal
- Expert Review of Clinical Pharmacology
- Published
- 2025-11-02
- DOI
- https://doi.org/10.1080/17512433.2025.2587174
- Primary Topic
- Hormonal Regulation and Hypertension
- Type
- article
- Field-Weighted Citation Impact
- 0.00